Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.
Despite the recent progress in interferon (IFN) therapies for chronic hepatitis C, liver cirrhosis remains refractory. One of the major obstacles to successful IFN therapy is low platelet count. Currently, splenic interventions, such as partial splenic embolization (PSE) or surgical splenectomy, have been applied effectively and make standard IFN therapy possible. However, there may be a group of patients with low platelet counts who can be treated without splenic intervention. We here report two patients with advanced type C liver cirrhosis who were successfully treated using very-low-dose pegylated interferon a2a plus ribavirin. One patient had a very low platelet count (2.5 x 10(4)/mul) due to splenomegaly before treatment. However, pretreatment serum HCV titers were low in both patients and early viral responses were obtained in both. Because PSE or splenectomy may still have some safety concerns, this attenuated IFN treatment protocol can be an alternative therapeutic option for patients with advanced type C liver disease, but good virological factors for sustained virological response.
Ohkoshi
Shogo
S
Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yamagiwa
Satoshi
S
Yano
Masahiko
M
Takahashi
Hiromichi
H
Aoki
Yo-Hei
YH
Matsuda
Yasunobu
Y
Aoyagi
Yutaka
Y
J Viral Hepat. 2006 Nov;13(11):762-9
17052276
J Gastroenterol. 2009;44(10):1009-15
19756352
Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3
16234063
Hepatol Res. 2008 Dec;38(12):1159-71
18684129
Nat Clin Pract Gastroenterol Hepatol. 2008 Nov;5(11):610-22
18838975
World J Gastroenterol. 2008 Oct 28;14(40):6140-4
18985803
J Gastroenterol. 2006 Jan;41(1):17-27
16501853
Clin Ther. 2004 Jul;26(7):991-1025
15336466
Hepatol Res. 2008 Mar;38(3):225-33
18034810
Eur J Gastroenterol Hepatol. 2005 Feb;17(2):179-84
15674095
J Hepatol. 2007 Oct;47(4):484-91
17692985
Ann Intern Med. 2003 Feb 18;138(4):299-306
12585827
Dig Dis Sci. 2002 Feb;47(2):388-91
11855556
NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
14768714
Hepatology. 2006 Dec;44(6):1543-54
17133492
Hepatol Res. 2008 Oct;38(10):980-6
18657124
Scand J Gastroenterol. 2008;43(11):1378-86
18615358
Hepatology. 2006 Dec;44(6):1675-84
17133499
Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1157-64
16215426
J Viral Hepat. 2007 Nov;14 Suppl 1:82-8
17958648
Hepatology. 2003 Sep;38(3):645-52
12939591
Antivir Ther. 2004 Dec;9(6):1027-30
15651761